Kumari Chandrawansa
Overview
Explore the profile of Kumari Chandrawansa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Higano C, George D, Shore N, Sartor O, Miller K, Conti P, et al.
EClinicalMedicine
. 2023 May;
60:101993.
PMID: 37251627
Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in...
2.
Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh S, Bodoky G, et al.
Mol Cancer Ther
. 2017 Jul;
16(10):2215-2222.
PMID: 28716815
Ramucirumab is an IgG monoclonal antibody specific for the vascular endothelial growth factor receptor-2. Ramucirumab, 8 mg/kg every 2 weeks, administered as monotherapy (REGARD) or in combination with paclitaxel (RAINBOW),...
3.
Fuchs C, Muro K, Tomasek J, Van Cutsem E, Cho J, Oh S, et al.
J Gastric Cancer
. 2017 Jul;
17(2):132-144.
PMID: 28680718
Purpose: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. Materials And...
4.
Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al.
Gastric Cancer
. 2015 Oct;
19(3):927-38.
PMID: 26510663
Background: We evaluated the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients previously treated for advanced gastric or gastroesophageal junction adenocarcinoma in Japanese and Western...
5.
Muro K, Oh S, Shimada Y, Lee K, Yen C, Chao Y, et al.
J Gastroenterol Hepatol
. 2015 Aug;
31(3):581-9.
PMID: 26317322
Background And Aim: East Asia has higher gastric cancer incidence and mortality rates than other regions. We present a subgroup analysis of East Asians in the positive study RAINBOW. Methods:...
6.
Wilke H, Muro K, Van Cutsem E, Oh S, Bodoky G, Shimada Y, et al.
Lancet Oncol
. 2014 Sep;
15(11):1224-35.
PMID: 25240821
Background: VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in combination with paclitaxel would increase overall survival in patients...
7.
Reidy D, Vakiani E, Fakih M, Saif M, Hecht J, Goodman-Davis N, et al.
J Clin Oncol
. 2010 Aug;
28(27):4240-6.
PMID: 20713879
Purpose: To evaluate the safety and efficacy of IMC-A12, a human monoclonal antibody (mAb) that blocks insulin-like growth factor receptor-1 (IGF-1R), as monotherapy or in combination with cetuximab in patients...
8.
Vahdat L, Pruitt B, Fabian C, Rivera R, Smith D, Tan-Chiu E, et al.
J Clin Oncol
. 2009 Apr;
27(18):2954-61.
PMID: 19349550
Purpose: Eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analog of the marine natural product halichondrin B. This open-label, single-arm, phase II study evaluated efficacy...